# SGNB6A-001 (NCT04389632)

> A Study of Sigvotatug Vedotin in Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04389632
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Seagen, a wholly owned subsidiary of Pfizer
- Conditions: Carcinoma, Non-Small Cell Lung; Squamous Cell Carcinoma of Head and Neck; HER2 Negative Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Esophageal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Ovarian Neoplasms; Cutaneous Squamous Cell Cancer; Exocrine Pancreatic Adenocarcinoma; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Stomach Neoplasms
- Interventions: sigvotatug vedotin; pembrolizumab; cisplatin; carboplatin
- Enrollment: 1006
- Primary outcome: Number of participants with adverse events (AEs)
- Primary outcome: Number of patients with laboratory abnormalities
- Primary outcome: Number of participants with dose-limiting toxicities (DLTs)

## Indexed commentary on SGNB6A-001 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=sgnb6a-001-nct04389632